Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure
BackgroundImmune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in patients with metastatic colorectal cancer (mCRC) characterized by high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). However, most patients experience intrinsic or acquired resistance....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1553380/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185486931329024 |
|---|---|
| author | Qianwen Huang Xiaoling Zheng Wenshen Xu |
| author_facet | Qianwen Huang Xiaoling Zheng Wenshen Xu |
| author_sort | Qianwen Huang |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in patients with metastatic colorectal cancer (mCRC) characterized by high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). However, most patients experience intrinsic or acquired resistance. The need for treatment for patients with MSI-H/dMMR mCRC remains unmet. Here, we report the case of a patient with dMMR mCRC who achieved a durable therapeutic benefit from the combination of ICI and angiogenesis inhibitor after ICI failure.Case presentationA 40-year-old Chinese woman diagnosed with cT4N2M1b mCRC characterized by dMMR attributed to MLH-1 and PMS-2 deficiency, along with KRAS mutation. Primarily, the patient was treated with a combination of Chinese medicine and XELOX and underwent disease progression. Due to dMMR status, this patient then received single-agent camrelizumab. Unfortunately, disease progression was observed after two cycles of treatment. Subsequently, she received camrelizumab combined with bevacizumab. After treatment, the patient achieved a complete response, and the disease was sustainably controlled with a progression-free survival (PFS) of 3 years and counting.ConclusionsThis report demonstrates that the combination of ICI and anti-angiogenesis therapy can induce a powerful and durable antitumor response in patients with ICI-resistant MSI-H/dMMR mCRC, which is worthy of further research. |
| format | Article |
| id | doaj-art-ff8d60563d66485ea732145eeedd5657 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ff8d60563d66485ea732145eeedd56572025-08-20T02:16:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-04-011510.3389/fonc.2025.15533801553380Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failureQianwen Huang0Xiaoling Zheng1Wenshen Xu2Department of Medical Oncology, Boluo County People’s Hospital, Huizhou, ChinaDepartment of Pharmacy, Boluo County People’s Hospital, Huizhou, ChinaDepartment of Medical Oncology, Boluo County People’s Hospital, Huizhou, ChinaBackgroundImmune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in patients with metastatic colorectal cancer (mCRC) characterized by high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). However, most patients experience intrinsic or acquired resistance. The need for treatment for patients with MSI-H/dMMR mCRC remains unmet. Here, we report the case of a patient with dMMR mCRC who achieved a durable therapeutic benefit from the combination of ICI and angiogenesis inhibitor after ICI failure.Case presentationA 40-year-old Chinese woman diagnosed with cT4N2M1b mCRC characterized by dMMR attributed to MLH-1 and PMS-2 deficiency, along with KRAS mutation. Primarily, the patient was treated with a combination of Chinese medicine and XELOX and underwent disease progression. Due to dMMR status, this patient then received single-agent camrelizumab. Unfortunately, disease progression was observed after two cycles of treatment. Subsequently, she received camrelizumab combined with bevacizumab. After treatment, the patient achieved a complete response, and the disease was sustainably controlled with a progression-free survival (PFS) of 3 years and counting.ConclusionsThis report demonstrates that the combination of ICI and anti-angiogenesis therapy can induce a powerful and durable antitumor response in patients with ICI-resistant MSI-H/dMMR mCRC, which is worthy of further research.https://www.frontiersin.org/articles/10.3389/fonc.2025.1553380/fullmetastatic colorectal cancerhigh microsatellite instabilitydeficient mismatch repairimmune checkpoint inhibitorsanti-angiogenesis therapy |
| spellingShingle | Qianwen Huang Xiaoling Zheng Wenshen Xu Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure Frontiers in Oncology metastatic colorectal cancer high microsatellite instability deficient mismatch repair immune checkpoint inhibitors anti-angiogenesis therapy |
| title | Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure |
| title_full | Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure |
| title_fullStr | Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure |
| title_full_unstemmed | Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure |
| title_short | Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure |
| title_sort | case report a long term response of immunotherapy combined with anti angiogenesis therapy in a patient with dmmr metastatic colorectal cancer after ici failure |
| topic | metastatic colorectal cancer high microsatellite instability deficient mismatch repair immune checkpoint inhibitors anti-angiogenesis therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1553380/full |
| work_keys_str_mv | AT qianwenhuang casereportalongtermresponseofimmunotherapycombinedwithantiangiogenesistherapyinapatientwithdmmrmetastaticcolorectalcanceraftericifailure AT xiaolingzheng casereportalongtermresponseofimmunotherapycombinedwithantiangiogenesistherapyinapatientwithdmmrmetastaticcolorectalcanceraftericifailure AT wenshenxu casereportalongtermresponseofimmunotherapycombinedwithantiangiogenesistherapyinapatientwithdmmrmetastaticcolorectalcanceraftericifailure |